• Mashup Score: 6
    ScienceDirect - 1 year(s) ago

    Read the latest articles of The Journal of Liquid Biopsy at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature

    Tweet Tweets with this article
    • Very proud of ISLB @isliquidbiopsy team launching the first issue of our “The Journal of Liquid Biopsy”, together with @CHematology our official journals. Thanks to authors, our board & @UmbertoMalapel1 our editor in chief for leading this journal! 👏👏 https://t.co/xp2CMI3bP9 https://t.co/oixKyulqVz

  • Mashup Score: 4

    Dr. Navneet Singh, MD DM (India) will moderate the program and lead the discussion and Q&A following panel presentations by Christian Rolfo, MD, Ph.D., MBA (USA …

    Tweet Tweets with this article
    • Looking forward to discuss tomorrow the highlights of #WCLC23 @IASLC with a great faculty! @cbaldotto @HendriksLizza and @ns_chd ! FLAURA2, AEGEAN, new TNM 9 Classification, PD-L1 tumor cell scoring and more https://t.co/a8U7jFo5V7 @isliquidbiopsy @TischCancer @LUNGevity https://t.co/0xqJXDk33X

  • Mashup Score: 0
    ISLB 2023 - ISLB 2023 - 1 year(s) ago

    Welcome to the5th Annual Congress of Liquid Biopsy Christian Rolfo ISLB President It is my greatest pleasure to welcome you all to the 5th Congress of Liquid Biopsy: “Opportunities and Challenges of Liquid Biopsy” (ISLB23) in our beautiful city of Madrid, Spain.  Liquid biopsy is a fascinating and exponentially growing field that has a tremendous … ISLB 2023 Read More »

    Tweet Tweets with this article
    • Congrats @ValsamoA and all the team for this elegant study! You’re paving the way for ctDNA #liquidbiopsy in IO response! 🚨This and more important insights will be presented by Dr Anagnstou at our Annual ISLB congress in Madrid on 19-21 November! #ISLB23 https://t.co/vRM2LCA32h https://t.co/pYpT8XbRAD

  • Mashup Score: 4

    V Workshop on Genomics NH Valencia Center, C/ de Ricardo Micó, 1, 46009 Valencia genomicscancer@doctaforum.com We use our own and third party cookies for the correct operation, display and use of the website by the user and to improve our services by collecting statistical data on the navigation of users on the website. You can learn more about the cookies we use and even reject them by viewing our Cookie Policy. By pressing the ‘Accept’ button you consent to the use of the above cookies. Functional

    Tweet Tweets with this article
    • Thanks @ElJanLe and thanks to Dr. Gil Bazo (Inst Valenciano de Oncologia) for the fantastic workshop! With the endorsement of @isliquidbiopsy @IASLC @_SEOM @GIDOncologia Great discussions! 🇪🇸🇪🇺🇺🇸@ojuan2001 @LuisRaezMD @NadalErnest @ElJanLe @AmeliaInsa https://t.co/B6xSEh93NO https://t.co/TgN7VQS6iu

  • Mashup Score: 6

    AbstractPurpose:. Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non–small cell lung cancer (NSCLC); however, a multicenter cohort of patients with EGFR-mutant lung cancers treated with osimertinib and selpercatinib for RET fusion–mediated osimertinib resistance has not previously been published.Patients and Methods:. Patients who received selpercatinib in combination with osimertinib on a prospective expanded access clinical trial (NCT03906331) and single-patient compassionate use programs across five countries were centrally analyzed. All patients had advanced EGFR-mutant NSCLC with a RET fusion detected from tissue or plasma following osimertinib therapy. Clinicopathologic and outcomes data were collected.Results:. Fourteen patients with EGFR-mutant and RET fusion–positive lung cancers who experienced prior progression on osimertinib received osimertinib and selpercatinib. EGFR exon 19 deletions (±T790M, 86%) and non-KIF5B fusi

    Tweet Tweets with this article
    • Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Cohort of EGFR-Mutant and RET Fusion + Lung Cancers ⁦@alexdrilon⁩ ⁦@JuliaRotow⁩ ⁦@RETpositive⁩ ⁦@RetRenegades⁩ ⁦⁦@EGFRResisters⁩ https://t.co/M1zbALu5u5

  • Mashup Score: 6
    PULCOR · Oncocor - 1 year(s) ago

    Curso multidisciplinario sobre cáncer

    Tweet Tweets with this article
    • Thanks to Dr Richardet FLASCA president for the kind invitation to participate in PulCor 2023 🇦🇷discussing #liquidbiopsy in Immunotherapy for Lung Cancer 🫁 sharing the session with @dlkaen and Dr. Rossell. @aaoncoclinica @isliquidbiopsy @OncoAlert https://t.co/VuxT7IQ1gq https://t.co/3wn5LtCyRV

  • Mashup Score: 0

    Abstract. cfDNA concentrations from patients with cancer are often elevated compared to that of healthy controls, but the sources of this extra cfDNA have never been determined. To address this issue, we assessed cfDNA methylation patterns in 178 patients with cancers of the colon, pancreas, lung, or ovary and 64 patients without cancer. Eighty-three of these individuals had cfDNA concentrations much greater than those generally observed in healthy subjects. The major contributor of cfDNA in all samples was leukocytes, accounting for ~76% of cfDNA, with neutrophils predominating. This was true regardless of whether the samples were derived from patients with cancer or the total plasma cfDNA concentration. High levels of cfDNA observed in patients with cancer did not come from either neoplastic cells or from surrounding normal epithelial cells from the tumor’s tissue of origin. These data suggest that cancers may have a systemic effect on cell turnover or DNA clearance.

    Tweet Tweets with this article
    • Very interesting paper on @CD_AACR on The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer #liquidbiopsy https://t.co/vQlBMOtd6i @isliquidbiopsy